Loading...
Docoh
Log in Free sign up

Icad (ICAD)

iCAD Inc., headquartered in Nashua, New Hampshire, is a medical-device manufacturer. iCAD makes cancer detection and radiation therapy devices. iCAD offers computer aided detection and workflow solutions to support detection of breast, prostate and colorectal cancers.

Company profile

Ticker
ICAD
Exchange
NASDAQ
Website
www.icadmed.com
CEO
Michael S. Klein
Employees
Incorporated
Delaware
Location
New Hampshire
Fiscal year end
Dec 31
Sector
Manufacturing > Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Industry (SIC)
Surgical & Medical Instruments & Apparatus
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
HOWTEK INC
SEC CIK
0000749660
Corporate docs
Subsidiaries
Xoft, Inc. • Xoft Solutions, LLC • iCad France, LLC • iCad Italy, LLC ...
IRS number
20377419

ICAD stock data

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
19 Aug 22
On Friday, 109 stocks hit new 52-week lows.
Lake Street Maintains Buy on icad, Lowers Price Target to $8
11 Aug 22
Lake Street analyst Frank Takkinen maintains icad (NASDAQ:ICAD) with a Buy and lowers the price target from $13 to $8.
icad: Q2 Earnings Insights
10 Aug 22
icad (NASDAQ:ICAD) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Earnings Scheduled For August 10, 2022
10 Aug 22
Earnings Outlook For icad
9 Aug 22

Press releases

From Benzinga Pro
iCAD Reports Financial Results For Second Quarter 2022
10 Aug 22
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
27 Jul 22
NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
6 Jun 22
NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in
iCAD Announces CFO Transition
25 May 22

Analyst ratings and price targets

Last 3 months
Current price
Average target
$8.00
Low target
$8.00
High target
$8.00
Lake Street
Maintains
Buy
$8.00
11 Aug 22
BTIG
Maintains
Buy
$8.00
24 Jun 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
19 Aug 22
31 Dec 22

Financial summary

Financial statements Chart ICAD financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.18M 27.18M 27.18M 27.18M 27.18M 27.18M
Cash burn (monthly) 872.67K 892.42K 1.04M 1.08M 853.33K 903.33K
Cash used (since last report) 1.47M 1.5M 1.75M 1.82M 1.43M 1.52M
Cash remaining 25.71M 25.68M 25.43M 25.36M 25.75M 25.66M
Runway (months of cash) 29.5 28.8 24.5 23.4 30.2 28.4

Beta Read what these cash burn values mean

Financial data from Icad earnings reports.

Recent insider trades

ICAD insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Apr 22 Klein Michael S Director stock option Common stock Grant Acquire A No No 7.2 30,000 216K 30,000
18 Mar 22 Stevens Stacey M Employee stock option Common Stock Grant Acquire A No No 4.15 200,000 830K 200,000
14 Mar 22 Stevens Stacey M Employee stock option Common Stock Grant Acquire A No No 3.93 200,000 786K 200,000
3 Mar 22 Timothy Norris Irish Common Stock Buy Acquire P No No 4.63 5,500 25.47K 5,500
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

ICAD institutional ownership history Ownership history
46.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 67 79 -15.2%
Opened positions 14 14 –
Closed positions 26 16 +62.5%
Increased positions 12 28 -57.1%
Reduced positions 33 29 +13.8%
13F shares Current Prev Q Change
Total value 53.87M 55.88M -3.6%
Total shares 11.83M 12.52M -5.6%
Total puts 25K 21.4K +16.8%
Total calls 17.3K 0 NEW
Total put/call ratio 1.4 Infinity NaN%
Largest owners Shares Value Change
Granahan Investment Management 2.44M $9.74M +2.8%
AIGH Capital Management 1.36M $5.44M NEW
Portolan Capital Management 1.1M $4.39M +21.2%
Vanguard 1.06M $4.22M -9.5%
Pura Vida Investments 672.99K $2.69M 0.0%
MS Morgan Stanley 404.61K $1.62M +13.6%
Worth Venture Partners 380.89K $1.62M NEW
BLK Blackrock 371.42K $1.49M -72.7%
Essex Investment Management 320.55K $1.28M +162.7%
Greenwood Capital Associates 225.73K $903K -0.4%
Largest transactions Shares Bought/sold Change
AIGH Capital Management 1.36M +1.36M NEW
BLK Blackrock 371.42K -987K -72.7%
Worth Venture Partners 380.89K +380.89K NEW
STT State Street 72.14K -295.46K -80.4%
Millennium Management 215.35K +215.35K NEW
First Eagle Investment Management 212.89K +212.89K NEW
Essex Investment Management 320.55K +198.54K +162.7%
Portolan Capital Management 1.1M +192.11K +21.2%
Renaissance Technologies 178.19K -178.2K -50.0%
Geode Capital Management 218.44K -169.88K -43.7%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Varian Medical Systems • Hologic • Sensus Healthcare

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: accelerate, ASUNo, brought, Daley, delivery, expanded, foot, half, Irvine, Italy, lessee, life, modification, opposed, rent, Sarno, small, square, Stephen, subscription, TheC, trend
Removed: ASU, Carter, manufacturer, month, remained
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
10-Q
2021 Q1
Quarterly report
4 May 21
10-K/A
2020 FY
Annual report (amended)
30 Apr 21
10-K
2020 FY
Annual report
15 Mar 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
Current reports
View all
8-K
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities
10 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 22
8-K
Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective
31 May 22
8-K
Entry into a Material Definitive Agreement
25 May 22
8-K
Results of Operations and Financial Condition
11 May 22
8-K
Company expects preliminary estimated revenue to be $7.5 million
21 Apr 22
8-K
Departure of Directors or Certain Officers
28 Mar 22
8-K
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation
28 Feb 22
8-K
Departure of Directors or Certain Officers
13 Jan 22
8-K
Company expects preliminary estimated Q4 2021 revenues to be between $7.8-$8.0 million
6 Jan 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
4 Mar 21
424B5
Prospectus supplement for primary offering
2 Mar 21
424B5
Prospectus supplement for primary offering
24 Apr 20
424B5
Prospectus supplement for primary offering
31 Mar 20
S-3
Shelf registration
10 Jan 20
S-8
Registration of securities for employees
18 Dec 19
424B5
Prospectus supplement for primary offering
13 Jun 19
424B5
Prospectus supplement for primary offering
12 Jun 19
424B3
Prospectus supplement
20 Feb 19
S-8
Registration of securities for employees
31 Jan 19
Proxies
View all
DEFA14A
Additional proxy soliciting materials
8 Jun 22
DEF 14A
Definitive proxy
2 May 22
DEF 14A
Definitive proxy
7 Jun 21
PRE 14A
Preliminary proxy
25 May 21
DEF 14A
Definitive proxy
27 May 20
PRE 14A
Preliminary proxy
14 May 20
DEF 14A
Definitive proxy
8 Nov 19
DEF 14A
Definitive proxy
20 Nov 18
DEF 14A
Definitive proxy
19 Oct 17
DEF 14A
Definitive proxy
3 Apr 16
Other
View all
SD
Conflict minerals disclosure
9 May 22
SD
Conflict minerals disclosure
28 May 21
SD
Conflict minerals disclosure
27 May 20
EFFECT
Notice of effectiveness
3 Feb 20
CORRESP
Correspondence with SEC
29 Jan 20
UPLOAD
Letter from SEC
14 Jan 20
SD
Conflict minerals disclosure
24 May 19
EFFECT
Notice of effectiveness
15 Feb 19
CORRESP
Correspondence with SEC
12 Feb 19
UPLOAD
Letter from SEC
11 Feb 19
Ownership
View all
SC 13G
ICAD / BlackRock ownership change
8 Jul 22
SC 13G
ICAD / HIRSCHMAN ORIN ownership change
6 Jul 22
3
ICAD / Stephen P Sarno ownership change
7 Jun 22
4
ICAD / Michael S Klein ownership change
21 Apr 22
4/A
ICAD / Stacey M Stevens ownership change
28 Mar 22
4
ICAD / Stacey M Stevens ownership change
23 Mar 22
4
ICAD / Jonathan Go ownership change
16 Mar 22
4
ICAD / Timothy Norris Irish ownership change
3 Mar 22
SC 13G
ICAD / Granahan Investment Management ownership change
13 Feb 22
SC 13G/A
ICAD / Portolan Capital Management ownership change
11 Feb 22

Patents

Utility
System and method for assessing breast cancer risk using imagery
21 Dec 21
This invention provides a system and method for assessing risk of a breast cancer diagnosis based upon imagery of tissue and (optionally) other patient-related factors.
Utility
System and Method for Assessing Breast Cancer Risk Using Imagery
27 May 20
This invention provides a system and method for assessing risk of a breast cancer diagnosis based upon imagery of tissue and (optionally) other patient-related factors.
Utility
Lung segmentation and bone suppression techniques for radiographic images
14 Oct 19
Lung segmentation and bone suppression techniques are helpful pre-processing steps prior to radiographic analyzes of the human thorax, as may occur during cancer screenings and other medical examinations.

Transcripts

View all
2022 Q2
Earnings call transcript
11 Aug 22
2022 Q1
Earnings call transcript
12 May 22
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
10 Nov 21
2021 Q2
Earnings call transcript
8 Aug 21
2021 Q1
Earnings call transcript
29 Apr 21
2020 Q4
Earnings call transcript
25 Feb 21
2020 Q3
Earnings call transcript
7 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2019 Q4
Earnings call transcript
28 Feb 20

Reddit threads

View all